Category list : European Medicines Agency (EMA)
Sort by: Newest first Oldest first A-Z Z-A
-
No-deal Brexit could see UK locked out of EU infectious disease surveillance data, chief medical officer warns
A no-deal Brexit could see the UK lose access to an EU-wide online tracker of infectious diseases and antimicrobial resistance, Dame Sally Davies, the chief medical officer for England, has told The Pharmaceutical Journal.
-
EMA recommends sartan manufacturers review processes to avoid contamination
The European Medicines Agency has recommended that manufacturers making sartan blood pressure medicines review their processes after impurities were found in a small number of products.
-
Brexit proposals only promises 'possibility' of ties with EMA
The Brexit political agreement does not guarantee ties with the European Medicines Agency, despite government ministers emphasising the importance of the need for close relationships with the drugs safety organisation in 2017.
-
More EMA staff expected to move to Amsterdam
The European Medicines Agency will lose fewer staff than feared when it moves from its London headquarters to a new home in Amsterdam after Brexit.
-
EMA confirms suspension or restriction of quinolone and fluoroquinolone antibiotics
The marketing authorisation of medicines containing cinoxacin, flumequine, nalidixic acid and pipemidic acid should be suspended and the use of the remaining fluoroquinolone antibiotics restricted, the European Medicines Agency has concluded following a 21-month review.
-
EMA to scale back work further after Christmas because of Brexit relocation
The European Medicines Agency has warned that it will have to cut down its work even further as it relocates from London to Amsterdam because of Brexit.
-
EMA committee recommends restrictions on use of quinolone and fluoroquinolone
A European Medicines Agency committee has recommended that the use of fluoroquinolone and quinolone antibiotics should be restricted following a review of their disabling and potentially long-lasting side effects.
-
Cancer patients in England 'first in Europe' to get access to CAR-T therapy
England will be the first country in Europe to offer patients with cancer access to “groundbreaking” new therapy, NHS England has announced.
-
FMD regulations won’t apply after ‘no-deal’ Brexit, says MHRA
Pharmacies will have no legal obligation to implement the Falsified Medicines Directive in the event of a ‘no-deal’ Brexit, the Medicines and Healthcare products Regulatory Agency has confirmed.
-
Fewer medicines at risk of supply disruption after Brexit as companies take action
The number of centrally authorised medicines that could have had their supply disrupted after Brexit has fallen from 108 to 39, according to the European Medicines Agency.
